Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples